FDA Inspection 1099165 — Shandong Luxi Pharmaceutical Co., Ltd.
The FDA completed an inspection of Shandong Luxi Pharmaceutical Co., Ltd. on July 24, 2019 in Heze. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- July 24, 2019
- Fiscal Year
- 2019
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Heze (China)